Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 126 clinical trials
Cellular Pharmacology and Platelet Effects of Abacavir and Lamivudine Anabolites

This study will evaluate the intracellular pharmacokinetics and platelet effects of abacavir (ABC), lamivudine (3TC), tenofovir alafenamide (TAF), and emtricitabine (FTC) in persons living with

  • 0 views
  • 25 Jan, 2021
  • 1 location
Pharmacokinetics of Intracellular TFV-DP and FTC-TP in HIV-infected Adolescents

Tenofovir (TFV) disoproxil fumarate (TDF) plus emtricitabine (FTC) or lamivudine (3TC) is the preferred nucleoside backbone of first-line antiretroviral therapy (ART) for adolescents in sub

HIV Vaccine
antiretroviral agents
tenofovir
hepatitis
lamivudine
  • 0 views
  • 23 Jan, 2021
  • 1 location
HIV Pre-exposure Prophylaxis Implementation Hong Kong Study

infection who fulfil eligibility criteria would be recruited. Eligible participants would receive one year of daily tenofovir disoproxil fumarate 300mg / emtricitabine 200mg (TDF/FTC) for free. A client

HIV Vaccine
immune globulin
hiv antibody
venereal disease
tenofovir
  • 0 views
  • 25 Jan, 2021
Evaluation of Pre-Exposure Prophylaxis Against HIV in Alpine Region

needed. Since 2009, several studies have shown that tenofovir disoproxil fumarate and emtricitabine (TDF/FTC), an antiretroviral therapy combining two nucleoside reverse transcriptase inhibitors used for

  • 0 views
  • 26 Jan, 2021
  • 8 locations
Real Life Study of Dolutegravir Plus Lamivudine in HIV-1-Infected Treatment-Naive Patients

treatment-nave patients GEMINI 1 &2, where efficacy of the dual therapy with DTG 50mg plus 3TC 300mg/QD was compared versus the efficacy of triple therapy with tenofovir disoproxil fumarate

  • 0 views
  • 23 Jan, 2021
  • 1 location
Identification of the Pre-exposure Prophylaxis (PrEP) Cascade for Women.

Pre-exposure prophylaxis (PrEP) is a daily pill that greatly reduces the risk of transmission of human immunodeficiency virus (HIV), however the barriers to PrEP use for women are understudied and PrEP is underutilized by women. Partnering with the DC Department of Health and the DC Center for AIDS Research (DC-CFAR), …

  • 11 views
  • 23 Jan, 2021
  • 2 locations